Split History
ETFs Holding ADMS »    ADMS Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Adamas Pharmaceuticals is a pharmaceutical company that discovers and develops chrono-synchronous therapies to improve the lives of people affected by chronic neurologic disorders. Co.'s portfolio includes: ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease; ADS-4101, a chrono-synchronous lacosamide therapy in clinical development for the treatment of partial onset seizures in patients with epilepsy; as well as Namenda XR® (memantine hydrochloride) extended-release capsules and Namzaric® (memantine hydrochloride extended-release and donepezil hydrochloride) capsules for the treatment of Alzheimer's disease. According to our ADMS split history records, Adamas Pharmaceuticals has had 2 splits.
ADMS split history picture
Adamas Pharmaceuticals (ADMS) has 2 splits in our ADMS split history database. The first split for ADMS took place on February 16, 1999. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. ADMS's second split took place on January 18, 2000. This was a 3 for 2 split, meaning for each 2 shares of ADMS owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as Adamas Pharmaceuticals splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the ADMS split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Adamas Pharmaceuticals shares, starting with a $10,000 purchase of ADMS, presented on a split-history-adjusted basis factoring in the complete ADMS split history. ADMS split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/10/2014
End date: 10/20/2017
Start price/share: $14.01
End price/share: $19.26
Dividends collected/share: $0.00
Total return: 37.47%
Average Annual Total Return: 9.43%
Starting investment: $10,000.00
Ending investment: $13,747.08
Years: 3.53
Date Ratio
02/16/19993 for 2
01/18/20003 for 2
ADMS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

ADPT Split History
ADXS Split History
AEZS Split History
AFAM Split History
AFFX Split History
AGN Split History
AHPI Split History
AIMT Split History
AIQ Split History
AIRM Split History

Astrotech (ASTC)
CHF Solutions, Inc. (CHFS)
Tandem Diabetes Care, Inc (TNDM)
Alliqua BioMedical, Inc. (ALQA)
Soleno Therapeutics, Inc. (SLNO)
InfoSonics Corporation (IFON)
Bioblast Pharma Ltd. (ORPN)
Rennova Health, Inc. (RNVA)
Diana Containerships Inc. (DCIX)
Ocean Rig UDW Inc. (ORIG)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

ADMS Insider Buying

ADMS Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.